Evidence map›Paper›PMID 32416769›Full record

ReviewThe Lancet. Respiratory medicine2020

Management of acute kidney injury in patients with COVID-19.

Claudio Ronco, Thiago Reis, Faeq Husain-Syed

Registry-linked trialAbstract readReview
In one paragraph

Review in The Lancet. Respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05060497 (DYNamic Assessment of Multi Organ Level Dysfunction in Patients Recovering From Covid-19), which is not on this map. Cited by 347 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
347citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05060497 completednot on this map

DYNamic Assessment of Multi Organ Level Dysfunction in Patients Recovering From Covid-19

TypeobservationalSponsorUniversity of NottinghamRan2020 to 2022Enrolled31ConditionsCovid19
3 · Its place in the literature

Who cites it

347 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Evaluation of muscle strength and renal function in survivors of severe COVID-19: A 12-month follow-up study.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2026
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Kidney involvement and anemia in COVID-19 infection.World journal of nephrology · 2025
    Review
  20. Article

287 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Claudio RoncoDepartment of Medicine, Università di Padova, Padua, Italy; Department of Nephrology, Dialysis and Kidney Transplantation, San Bortolo Hospital, Vicenza, Italy; International Renal Research Institute of Vicenza, Vicenza, Italy. Electronic address: cronco@goldnet.it.
Thiago ReisInternational Renal Research Institute of Vicenza, Vicenza, Italy; Department of Nephrology, Clinica de Doenças Renais de Brasilia, Brasilia, Brazil.
Faeq Husain-SyedInternational Renal Research Institute of Vicenza, Vicenza, Italy; Department of Internal Medicine II, Division of Nephrology, Pulmonology and Critical Care Medicine, Member of the German Centre for Lung Research, University Hospital Giessen and Marburg, Giessen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. Most patients with COVID-19 have mild symptoms, but about 5% develop severe symptoms, which can include acute respiratory distress syndrome, septic shock, and multiple organ failure. Kidney involvement is frequent, with clinical presentation ranging from mild proteinuria to progressive acute kidney injury (AKI) necessitating renal replacement therapy (RRT). An understanding of the pathophysiology and mechanisms of kidney damage and AKI in the setting of critical illness and COVID-19 is emerging, although further research is needed to identify patients at risk of AKI and to guide management strategies. As no specific treatment options exist for AKI secondary to COVID-19, intensive care is largely supportive. Current approaches to prevention and management of AKI, and identification of potential indications for use of RRT and sequential extracorporeal therapies, are based mainly on clinical experience, and AKI strategies are adapted empirically to patients with COVID-19. International collaborative and cross-disciplinary research is needed to obtain adequate evidence to support current clinical approaches and to develop new approaches to management.

Indexed as

BetacoronavirusAcute Kidney InjuryCoronavirus InfectionsCOVID-19Critical CareCritical IllnessHumansPandemicsPneumonia, ViralSARS-CoV-2

Identifiers

PMID32416769
PMCPMC7255232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.